Ligand Pharmaceuticals (LGND)
| Bid | 105.56 |
| Market Cap | 2.03B |
| Revenue (ttm) | 169.61M |
| Net Income (ttm) | -4.09M |
| EPS (ttm) | -0.22 |
| PE Ratio (ttm) | -480.23 |
| Forward PE | 19.25 |
| Analyst | Buy |
| Ask | 105.97 |
| Volume | 47,963 |
| Avg. Volume (20D) | 122,987.4 |
| Open | 104.95 |
| Previous Close | 105.14 |
| Day's Range | 102.61 - 107.37 |
| 52-Week Range | 67.72 - 129.90 |
| Beta | 1.03 |
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease ca...
Analyst Forecast
According to 6 analyst ratings, the average rating for LGND stock is "Buy." The 12-month stock price forecast is $141.5, which is an increase of 33.93% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Ligand Pharmaceuticals Incorporated (LGND) Q4 2024 Earnings Call TranscriptLigand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Melanie Herman - Senior Director of Financial Planning and Analysi...
